That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only one for which DOACs do not have a better risk profile ...

Semaglutide is revolutionizing kidney disease treatment for type 2 diabetes patients. Learn how it works and its potential ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

[13] Furthermore, greater recognition, prevention, and treatment of AF may reduce the risk for other known cardiovascular and kidney complications in patients with CKD.

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue them or never receive a prescription due to ...

less invasive treatment option. The Medtronic PulseSelect™ Pulsed Field Ablation System uses pulsed electric fields to target and eliminate the muscle cells that cause AFib. This innovative ...

An irregular heartbeat can raise your risk for heart failure and stroke. With up to 6 million Americans estimated to have ...

Boston Scientific Corp. reported positive data for two key atrial fibrillation therapies at AF Symposium 2025 on January 17.